Clinical Study to Investigate the Effectiveness of the TOPAS System to Treat Fecal Incontinence

Not Applicable

Completed

• Conditions: Fecal Incontinence
• Interventions: Device: TOPAS Treatment for Fecal Incontinence

• Registration Number: NCT01090739
• Lead Sponsor: ASTORA Women's Health

Brief Summary

The purpose of this study is to demonstrate that the TOPAS System effectively treats fecal incontinence in women as measured by a 50% reduction in the number of FI episodes in a 14 day bowel diary at 12 months.

Detailed Description

This is a prospective, multi-center, single-arm, open-label, two- stage, adaptive study conducted to obtain data to demonstrate the safety and effectiveness of the TOPAS system for the treatment of FI in women who have failed conservative therapy. It was approved by the FDA for up to 152 implanted subjects at up to 15 investigational sites in the US. Eight study centers are led by a Colorectal Surgeon and seven centers are led by an Urogynecologist.

This study is being conducted in compliance with Title 21 CFR Parts 11, 50, 54, 56, and 812; the principles of GCP as set forth in the World Medical Association Declaration of Helsinki (2008); and the ISO standard 14155:2011 (Clinical investigation of medical devices for human subjects - Good clinical practice).

Study Timeline

• Study First Submitted: 2010-03-19
• Study First Submitted QC: 2010-03-19
• Study First Posted: 2010-03-22
• Study Start: 2010-04
• Primary Completion: 2013-11
• Disposition First Submitted: 2015-01-15
• Disposition First Submitted QC: 2015-01-15
• Disposition First Posted: 2015-01-27
• Study Completion: 2016-04
• Results First Submitted: 2016-04-19
• Status Verified: 2016-08
• Results First Submitted QC: 2016-08-25
• Last Update Submitted: 2016-08-25
• Results First Posted: 2016-08-26
• Last Update Posted: 2016-08-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 207

Inclusion Criteria

Subject is/has:

1. An adult (>/= 18 years) female.
2. FI symptoms for a minimum of 6 months.
3. Failed two modalities of conservative therapies such as Dietary Modification, Pharmacologic Intervention, or Pelvic Floor Muscle Training.
4. <50 years old OR if >/= 50 years old, has had a negative cancer screening examination of the colon according screening guidelines (colonoscopy or barium enema + flexible sigmoidoscopy) within the past 3 years prior to informed consent date. (Note: if not done, the investigating physician must provide written justification for not having this exam and must be following the American Cancer Society Guidelines).
5. FI episodes ≥ 4 in 14 day period.

Exclusion Criteria

Subject is/has

1. Unable or unwilling to sign Informed Consent Form or comply with study requirements.
2. Currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound the results of this study as determined by AMS.
3. Allergic to polypropylene.
4. Pregnant or planning a future pregnancy.
5. Less than 12 months (365 days) postpartum.
6. Pelvic prolapse >/=1 cm beyond the hymen (Stage III & IV)
7. Had stress urinary incontinence (SUI) or anterior repair within 3 months (90 days) prior to TOPAS Sling System implantation.
8. Had a hysterectomy, Sphincteroplasty, or Posterior surgery within 6 months (180 days) prior to TOPAS Sling System implantation.
9. Had rectal surgery (such as rectopexy) within 12 months (365 days) of TOPAS Sling System implantation.
10. Planning pelvic surgery within 12 months (365 days) post implant
11. Current Grade III or IV hemorrhoids.
12. Neurological or psychological condition as cause of FI such as MS, dementia, brain tumor.
13. Diagnosed Inflammatory Bowel Disease (for example, ulcerative colitis or Crohn's disease).
14. Chronic, watery diarrhea, unmanageable by drugs or diet, as primary cause of fecal incontinence.
15. Severe chronic constipation, including obstructive defecatory disorder.
16. External full thickness rectal prolapse.
17. A history of laxative abuse within the past 5 years.
18. Had previous rectal resection.
19. Active pelvic infection, perianal or recto-vaginal fistula.
20. Congenital anorectal malformations or chronic 4th degree lacerations and cloacae.
21. History of therapeutic radiation for cancers of the pelvis.
22. Currently implanted with a sacral nerve stimulator.
23. Contraindicated for surgery or having any condition that would compromise wound healing.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
TOPAS	TOPAS Treatment for Fecal Incontinence	TOPAS Treatment for Fecal Incontinence

Primary Outcome Measures

Name	Time	Method
Percentage of Responders	12 Months	The primary endpoint for efficacy is the 14 day bowel diary documenting liquid or solid fecal incontinence episodes. A 50% reduction in the number of FI episodes is considered a treatment responder.

Secondary Outcome Measures

Name	Time	Method
Change in Urge Fecal Incontinence Episodes	36 Month Follow-up Visit	Number of urge fecal incontinence episodes in a 14 day period
Change in Fecal Incontinence Days	36 Month Follow-up Visit	Number of fecal incontinence days in a 14 day period
Change in Wexner Symptom Severity Score	36 Month Follow-up Visit	Wexner Symptom Severity Score for fecal incontinence (also known as the Cleveland Clinic Incontinence Score) as described by Jorge and Wexner, 1993 (Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993 Jan;36(1):77-97). Measured on a 0-20 scale with lower scores equal to less fecal incontinence.
Change in Fecal Incontinence Quality of Life Score	36 Month Follow-up Visit	Fecal Incontinence Quality of Life Score as described by Rockwood et al., 2000 (Rockwood TH, Church JM, Fleshman JW, Kane RL, Mavrantonis C, Thorson AG, Wexner SD, Bliss D, Lowry AC. Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence. Dis Colon Rectum. 2000 Jan;43(1):9-16; discussion 16-7). Four domains of lifestyle, coping, depression, and embarrassment. Measured on a 0-4 scale with higher scores equal to better quality of life.
Change in Pelvic Floor Impact Questionnaire (PFIQ-7) Scores	36 Month Follow-up Visit	Short-form version of the Pelvic Floor Impact Questionnaire (PFIQ-7) as described by Barber et al., 2005 (Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7. Am J Obstet Gynecol. 2005 Jul;193(1):103-13).; The short-form version of the Pelvic Floor Impact Questionnaire has a total of 7 questions and 3 scales (Urinary Impact, Pelvic Organ Prolapse Impact, and Colorectal-Anal Impact). Total PFIQ score measured on a 0-300 scale with higher scores equal to greater pelvic floor impact. Subscales scored on 0-100 scale and the higher the score the greater pelvic floor impact, exactly like the Total PFIQ score.
Change in Fecal Incontinence Episodes	36 Month Follow-up Visit	Number of fecal incontinence episodes in a 14 day period
Change in Pelvic Floor Distress Inventory (PFDI-20) Scores	36 Month Follow-up Visit	Short-form version of the Pelvic Floor Distress Inventory (PFDI-20) as described by Barber et al., 2005 (Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7. Am J Obstet Gynecol. 2005 Jul;193(1):103-13).; The short-form version of the Pelvic Floor Distress Inventory has a total of 20 questions and 3 scales (Urinary Distress Inventory, Pelvic Organ Prolapse Distress Inventory, and Colorectal-Anal Distress Inventory). Total PFDI score measured on a 0-300 scale with higher scores equal to greater pelvic floor distress. As with the Total PFDI Score, higher subscale scores equal greater pelvic floor distress, on a 0-100 scale.
Change in Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12)	36 Month Follow-up Visit	Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12) as described by Rogers RG, Coates KW, Kammerer-Doak D, Khalsa S, Qualls C. A short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). Int Urogynecol J Pelvic Floor Dysfunct. 2003 Aug;14(3):164-8; discussion 168. Measured on a 0-48 scale with higher scores equal to better sexual function.
Change in Numeric Pelvic Pain Scale (NPPS)	12 Month Follow-up Visit	Numeric Pelvic Pain Scale (NPPS) adapted from McCafferty M, Pasero C. Pain: Clinical Manual. 2nd ed. Philadelphia: Mosby Inc.; 1999. Chapter 3, Assessment Tools; p. 58-75. The NPPS is scored on a 0-10 scale with higher scores indicating more severe pain. Since the NPPS was introduced later in the study, earlier implanted subjects did not have the baseline NPPS score and a change from baseline could not be calculated.

Trial Locations

Locations (14)

Abbott Northwestern Hospital; 🇺🇸 Minneapolis, Minnesota, United States

University of California SF - Mt Zion Medical Center; 🇺🇸 San Francisco, California, United States

Cleveland Clinic Foundation - Florida; 🇺🇸 Weston, Florida, United States

University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States

Raybon OB-GYN; 🇺🇸 Toccoa, Georgia, United States

University of North Carolina - Chapel Hill; 🇺🇸 Chapel Hill, North Carolina, United States

The Christ Hospital; 🇺🇸 Cincinnati, Ohio, United States

Cleveland Clinic Foundation - Ohio; 🇺🇸 Cleveland, Ohio, United States

St. Luke's Hospital; 🇺🇸 Allentown, Pennsylvania, United States

University of Oklahoma; 🇺🇸 Oklahoma City, Oklahoma, United States

Womens Hospital of Texas; 🇺🇸 Houston, Texas, United States

Sacred Heart Medical Center; 🇺🇸 Spokane, Washington, United States

Atlantic Health System; 🇺🇸 Morristown, New Jersey, United States

University of South Florida; 🇺🇸 Tampa, Florida, United States